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Sweden has many registers to monitor and follow-up healthcare, and combined with the 
unique personal identification numbers, this represents vast opportunities for register based 
research. Part of these data sources are the Swedish quality registers, which are set up to 
monitor the quality of care of specific diseases. Two of these registers that both have good 
national coverage over time and are used for research purposes are the Swedish 
Rheumatology Quality Register (SRQ) and the Swedish Stroke Register (Riksstroke). These 
are set up to monitor the quality of care of patients with rheumatoid arthritis (RA) and stroke, 
respectively, both diseases being associated with a chronic condition of functional disability. 
Data from the two quality registers have been used for scientific research in various fields, 
but to a lesser extent in health economic analyses.   
Health economics addresses issues relating to the allocation of scarce resources to improve 
health. This includes resource allocation both within the economy to the healthcare system 
and within the healthcare system to different activities. Two common health economic 
approaches are economic evaluations of specific therapies and burden-of-illness studies, 
taking a broader analytical approach to a disease.  
The overall aim of this thesis was to study the applicability of quality register data in health 
economic analyses of chronic conditions. The specific aims were:  
• To assess the applicability of data from a quality register in economic evaluations of 
anti-TNF treatment for RA in clinical practice 
• To assess the applicability of data from a quality register in burden-of-illness studies 
where health outcomes, resource use and costs of stroke are put in relation to each 
other 
Data from the quality registers were used and linked to other relevant data sources to address 
the aims of this thesis. For the economic evaluations of treatments in RA, health economic 
models were constructed to enable the analyses. Statistical analyses were performed to allow 
for hospital comparisons of health outcomes and resource use for stroke, as well as estimating 
long-term transition probabilities for the health economic model in RA.  
The papers concluded that: 
• Anti-TNF therapies have on macro level been used cost-effectively as first-line 
biological treament for RA in Swedish clinical practice. The cost-effectiveness results 
did not differ depending on the source of effectiveness data (clinical practice or RCT 
trial). However, the results were sensitive to the underlying progression rate of the 
comparator and assumptions made in the model. 
• The impact of stroke on health outcomes, resources and costs were substantial. There 
were differences in performance between hospitals in these indicators that could not 
be explanied by differences in patient mix. The results further indicated that the costs 
differed by level of functional disability and age, up to two years post stroke.  
Further, the papers of this thesis demonstrated the valuable contribution of quality register 
data in health economics in providing a valid base of data and opportunities to: 
• Assess real life effectiveness of treatments in economic evaluations 
• Retrieve data on health outcomes and patient characteristics, which are essential in:  
o Measuring health outcomes and relating them to levels of resource use 
o Enabling hospital comparisons of performance and performing case-mix 
adjustment of results 
o Enabling stratification of cost estimates by level of health outcome 
o Provide input parameters for future economic evaluations 
In order to assess the full health economic aspects of chronic conditions, quality registers play 
an important role, but there is a necessity to combine the quality register data with other 
registers or other data sources, published literature and potentially also conduct modelling to 
account for the long-term effects. Nevertheless, any quality register that wants to ensure that 
the data can be used for health economic analyses and provide valid data for such analyses, 
should consider to: 
• Ensure long-term follow-up of the patients (espcecially in chronic conditions) 
• Collect data on: 
o Patient characteristics, including the clinical markers important for the 
patient’s prognosis 
o Treatments received  
o Health outcomes that are common as measurements of treatment outcome (e.g 
in RCTs), as well as estimation of quality of life or utilities 
o Resource use (quantifyable) outside the healthcare sector, e.g. informal care 
The quality registers and other register data sources can be utilized to a greater extent in 
different assessments which share the aim of improving healthcare delivery and increasing its 
value – either by assessing level of health outcomes, processes and resources used; enabling 
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1 INTRODUCTION 
Sweden has many registers to monitor and follow-up healthcare. The personal identification 
numbers of individuals in Sweden are included in each of these registers, providing a 
unique opportunity to link data and perform evaluations on real life retrospective data over 
a range of aspects. Part of this flora of registers are held by the Swedish quality registers 
which are set up to follow diagnosis- and disease-specific health outcomes and healthcare 
processes in order to monitor the quality of healthcare (www.kvalitetsregister.se). There are 
more than 100 quality registers in Sweden, out of which approximately half are suitable for 
scientific research purposes. The quality registers can cover a wide range of variables, 
including healthcare resource use (such as length of stay or imaging procedures), clinical 
markers, patient reported outcome measures (PROM) and patient reported experience 
measures (PREM). Two of these registers that both have good national coverage over time 
and are used for research purposes are the Swedish Rheumatology Quality Register (SRQ) 
and the Swedish Stroke Register (Riksstroke), which are set up to monitor the quality of 
care of patients with rheumatoid arthritis (RA) and stroke, respectively.  
Rheumatoid arthritis is a chronic auto-immune progressive disease that leads to restricted 
joint mobility, chronic pain, fatigue and functional disability. It usually has its onset in mid-
life which means that patients can live with the disease and associated disability for many 
years (1). It is important to initiate effective treatment early in the course of the disease to 
limit the long-term effects on function, ability to perform daily activities and permanent 
damage of the joints.  
Stroke is an acute disease caused by bleeding or ischemia in the brain. Early acute 
treatment is vital for survival and minimizing brain damage due to the stroke. Many 
patients have remaining disabilities after their stroke due to brain damage, with life-long 
consequences on, for example, the ability to perform daily activities (2).  
Both RA and stroke are associated with chronic disability throughout the remaining life of 
the patient, although with different reasons for this disability. This has consequences on the 
health-related quality of life (HRQoL) of the individual patients (3), as well as a notable 
impact on society at large, in terms of both direct and indirect costs (primarily for RA) (4-
9). Health economic analyses taking such effects into account can aid decision makers in 
ensuring cost-effective management of these patients in the long term. The SRQ and 
Riksstroke both contain information that are of importance in health economic analyses of 
RA and stroke, respectively, although they were not originally designed for health 
economic purposes. This thesis therefore assesses the applicability of quality register data 
in health economic analyses of these two chronic conditions.  
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1.1 RHEUMATOID ARTHRITIS 
1.1.1 Pathophysiology 
Rheumatoid Arthritis is a chronic auto-immune progressive disease characterized by 
inflammation. The immune system normally produces antibodies that attack bacteria or 
viruses to help fight infection. In RA, the immune system is instead attacking its own tissue, 
sending antibodies and/or autoreactive T-lymphocytes to the lining of the joints where they 
attack surrounding tissue. This causes the thin layer of cells (synovial membrane) covering 
the joints to become sore and inflamed, releasing inflammatory cytokines and enzymes that 
damage nearby bones, cartilage, tendons and ligaments. This causes the joints to lose its 
shape and alignment and eventually get completely destroyed. The cytokines damaging the 
joints are primarily Tumour Necrosis Factor (TNF) and Interleukin (IL-1 and IL-6), which 
also stimulates inflammation in patients RA (10).   
In RA, the most relevant autoimmune antibodies are the Rheumatoid Factor (RF) and anti-
cyclic citrullinated peptide (anti-CCP). Laboratory tests can give an indication on the level of 
RF and anti-CCP present in the blood, which are considered predictors of the development of 
the disease. 75% of patients with RA show positive tests for RF and/or anti-CCP (11). B-cells 
are the source of RF and anti-CCP, and B-cells also contribute to T-cell activation through 
expression of stimulatory molecules (12). A simplified illustration over the pathophysiologic 
pathways in rheumatoid arthritis and their main clinical consequences is depicted in Figure 1. 
High inflammatory activity and early joint erosion in the course of the disease is considered 
to be an indication for poor prognosis with fast disease progression (13).  
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Figure 1. Simplified pathophysiologic pathways in rheumatoid arthritis and their main clinical consequences. Printed with 
permission from v Vollenhoven (10). Abbreviations: ACPA, anti‑citrullinated protein/peptide antibodies; APC, antigen 
presenting cell; GM‑CSF, granulocyte‑macrophagecolony‑stimulating factor; IL, interleukin; RF, rheumatoid factor; TNF, 
tumour necrosis factor; TREG, regulatory T cell. 
1.1.2 Epidemiology 
The prevalence of rheumatoid arthritis is estimated to be 0.5–1.0 % worldwide (1), but the 
progressive nature of the disease and its onset in early or middle life means that patients can 
live for 30 or more years with the disease (1). The total number of patients with RA has been 
estimated to almost 2 million people in Europe and approximately 40,000 prevalent cases in 
Sweden (14). RA is more common among women than men, with a reported men-to-women 
ratio at 1:2 to 1:3 (14), but a higher proportion of men has been reported in the age group 45 
to 64 (15). 
An increased mortality rate has been noted for patients with RA, most often caused by 
cardiovascular disease (11). Other results of RA-related mortality are inconclusive; some 
studies have indicated that there was an increased mortality linked to functional status and 
disease activity whereas other studies were not able to demonstrate such an increase in 
mortality associated with RA during the first 10 years of follow-up (16-21).  
The main effect of RA is the consequences on the patients’ quality of life, as the disease can 
rapidly lead to restricted joint mobility (tender and swollen joints), chronic pain, fatigue, and 
functional disability. Approximately 20% of patients are unable to work during the years 
following the diagnosis (22) and one-third of the patients are unable to work within 10 years 
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of disease onset (4-6). The disease therefore has a considerable social and economic impact, 
and the costs to society associated with RA are substantial, both in terms of indirect and 
direct costs. 
The cause of RA is unclear but more recent research has indicated that smoking can explain 
approximately 20% of the origin (11). Part of RA onset is explained by environmental factors 
and genetic predisposition (23), and potentially also by hormones as RA is more common in 
women than in men and often emerge while entering menopause (www.nhs.uk, 
www.1177.se).   
1.1.3 Treatments  
Early and correct diagnosis of RA is important to be able to initiate effective treatment and 
minimize the occurrence of joint destruction. Available treatments include both 
physiotherapy, which is important in order to maintain muscle strength and quality of life 
(11), and pharmaceutical treatments. As RA is a chronic disease, treatments are necessary 
during the remainder of the patient’s life.  
There are today several different types of pharmaceutical treatments available for patients 
with RA. Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are available 
to suppress inflammation (and relieve pain in the case of NSAIDs). Disease modifying 
antirheumatic drugs (DMARDs) are however more effective to suppress inflammation and 
thereby reduce the degradation of cartilage and bone. This in turn reduces the risk of 
permanent destruction of the joints. DMARDs can be non-biological or biological. Non-
biological DMARDs act broadly on components active in RA, acting as anti-inflammatory or 
anti-metabolite agents (10). Non-biological DMARDs, specifically methotrexate (MTX) 
became more common in the 1990s, with intensified use earlier in the course of the disease 
(14), making a significant difference to the projected outcome for the patients. MTX is today 
commonly used as first-line therapy (11). 
Biological DMARDs became available in 1999 with the ability to not only effectively control 
inflammation but prevent or slow the development of irreversible joint erosion (14). 
Biological DMARDs include the anti-tumour necrosis factor agents (anti-TNFs) available 
since 1999, and other biological agents have become available in more recent years for the 
treatment of RA. The biological DMARDs block TNF, IL-1, IL-6 or B-cells producing RF 
and anti-CCP, dependent on the biological regimen (10) (see Figure 1). This development of 
different biological DMARDs provides an opportunity for patients to switch to alternative 
treatments if a treatment regimen has no or diminishing effect on disease progression (11). 
The treatments also have different modes of administration which may impact the choice of 
treatment regimen (for example is infliximab administered intravenous whereas the other 
anti-TNFs are administrated by infusion). Treatment results in newly diagnosed patients have 
improved continuously in recent years, following this development of biological DMARDs, 
where more patients now are in a state of low disease activity with limited functional 
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disability (11). More recent studies are also assessing different treatment schemes in early RA 
to minimize permanent damage (10) and ensure cost-effective use of treatment alternatives. 
1.1.4 Treatment outcome 
In randomized clinical trials (RCTs), there are two common treatment response criteria used; 
The American College of Rheumatology (ACR) response and the European League Against 
Rheumatism (EULAR) Disease Activity Score (DAS).  
The ACR criterion is defining response as a percentage change from baseline in a core set of 
clinically relevant variables. 20% response (ACR20) is classified as a responder, but ACR50 
and ACR70 are also often used as measures of response to capture the effect of biological 
DMARDs (24).  
Classification of a responder on DAS is taking into account change in disease activity and 
current state of disease activity of the patients (24). In DAS28 (28 tender and swollen joint 
count) the scale is from 0-10, where a score below 3.2 indicates low disease activity and a 
score below 2.6 indicates a state of remission.  
The Health Assessment Questionnaire Disability Index (HAQ) is another index used for 
assessment of functional status (10) on a scale of 0-3 where 0 is minimal functional disability. 
HAQ has been found to be strongly correlated to patients’ quality of life and costs (25) and is 
often used in health economic analyses of RA. 
1.2 STROKE 
1.2.1 Pathophysiology  
Stroke is defined by WHO as “rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to 
death, with no apparent cause other than of vascular origin” (26). However, there is an 
ongoing discussion about updating this definition to adapt to advances in science and 
technology, for example the 24-hour inclusion criterion is questioned as permanent injury can 
occur much sooner (27).  
Nevertheless, stroke is a general term for conditions with common effects; decreased or 
completely blocked circulation in the brain's blood vessels which results in lack of function 
and, after a time, cell death in the affected parts of the brain. This in turn causes a risk of 
death or impairment of bodily function which may be substantial. A stroke can be caused by 
a blood clot (ischemia) or bleeding (haemorrhage), either intracerebral or subarachnoid (see 
Figure 2).  
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Figure 2. Illustration of ischemic stroke and intracerebral haemorrhage. Printed with permission from Ikumi Kayama 
(www.studiokayama.com)  
An ischemic stroke (IS) is most commonly caused by a clot in the blood vessels in the brain 
or the neck, which leads to oxygen deficit in the affected area. If the clot has emerged in the 
occluded vessel it is called a thrombosis, mainly caused by atherosclerosis in the main vessel 
of the brain (28, 29). If the clot has emerged in a distant vessel (often a stenosis of the carotid 
artery) or in the heart (often due to atrial arrhythmias or faulty valves), it is referred to as 
emboli (29). Blood clots stuck in the brain's large vessels cause the most serious damage, 
especially when in arteria cerebri media (30). 
The subtypes of IS have different aetiologies, risk factor profiles and different risks of 
mortality and new vascular events. The subtypes may be classified according to TOAST (31) 
in five categories;   
• Cardioembolism, when the stroke is caused by an embolus arising in the heart, often 
associated with atrial fibrillation. 
• Large artery atherosclerosis, caused by stenosis or occlusion of a major brain artery or 
branch cortical artery, presumably due to atherosclerosis.  
• Small-vessel occlusion in the central brain, often labeled as lacunar infarcts. These 
patients often have a history of diabetes mellitus or hypertension. 
• Other determined etiology, includeing patients with rare causes of stroke, such as 
nonatherosclerotic vasculopathies, hypercoagulable states, or hematologic disorders. 
• Undetermined etiology, when cause cannot be determined with any degree of 
confidence or two or more potential causes are identified. 
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Blood clots can be dissolved naturally within a short time, and thereby present a state of 
temporary stroke symptoms, called transient ischemic attack (TIA). A TIA is a warning of a 
high risk (10%) for actual stroke within two days, and TIA is therefore devoted considerable 
attention in the preventive work of stroke (30, 32). 
A haemorrhagic stroke occurs when a blood vessel in the brain bursts (not because of 
trauma) with increased pressure and compression of surrounding tissue as a result (28). Brain 
haemorrhages can be classified based on where in the brain rupture occurs; inside the brain 
tissue (intracerebral [ICH], 10% of all strokes), respectively outside the brain tissue 
(subarachnoid [SAH], 5% of all strokes). SAH also yields a diffuse brain injury in contrast to 
the focal consequences of the other stroke types, and therefore has a different recovery 
trajectory. 
1.2.2 Epidemiology 
In Sweden, approximately 25,000 patients suffer an IS or ICH each year (2), out of which 
approximately 85% suffer from IS and 15% from ICH. Approximately 75% of these patients 
are having their first stroke, the rest are recurrent strokes. In addition to strokes, 
approximately 10,000 cases of TIA occur annually in Sweden. Over 80% of all IS or ICH 
cases affect individuals who are older than 65 years and are rather evenly distributed between 
men and women, although women on average are older at the time of their stroke (33). Stroke 
incidence has declined by approximately 1% annually since 2004 (34).  
Risk factors for stroke are widely known and to a large extent potentially avoidable or 
treatable, except for age and sex (33, 35) (see Figure 3). The factors differ between the 
different subtypes of stroke, but are dominated by high blood pressure (hypertension) for both 
IS and ICH, and presence of cardiovascular source for emboli such as atrial fibrillation or 
narrowing of carotid arteries for IS (35, 36). Diabetes causes a moderate increase in stroke 
risk (35, 36). Smoking and obesity have also been shown to be associated with an increased 
risk of stroke (35, 37). Congenital heart defects and disorders of normal coagulation can for 
example also cause a stroke (28, 38). Several studies have indicated that significant portions 
of the lower mortality from stroke in recent decades probably can be attributed to better 
primary prevention therapy, primarily of high blood pressure (28, 36, 38).  
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Figure 3. Patient attributable risks (PAR, %) of preventable risk factors for stroke for Western Europe, North America and 
Australia. Constructed from INTERSTROKE (35). Results adjusted for age, hypertension, smoking, waist-to-hip ratio, 
diabetes, physical activity, mAHEI, alcohol intake, psychosocial factors, apolipoproteins and cardiac causes were included in 
each model. *IS only 
In Sweden, stroke is the most common cause of functional disability in adults and the third 
most common cause of death, after heart attack and cancer (2). The mortality rate is slightly 
higher for women than for men (2) and recent studies have shown that ICH account for half 
of all deaths from stroke, although IS is much more common (39). Many patients have 
remaining impairments after a stroke with life-long consequences on functioning (2) and 
healthcare costs (7-9). Hence, the effects of stroke on morbidity, mortality and costs both for 
the individual and for society are substantial (40, 41). 
1.2.3 Treatments  
Early acute treatment is vital for survival and minimizing brain damage after a stroke. Access 
to acute therapies has increased in recent years, which has had positive impact on the 
prognosis of the patients’ health and has put increased emphasis on ensuring fast access to 
emergency care after stroke onset. 
In principle, all incoming patients undergo a neuroradiological imaging (usually computed 
tomography, CT) to clarify whether the stroke is caused by a clot or a bleeding, as this 
determines the acute treatment options. In the case of IS, there are reperfusion treatments 
available as of recent years, namely thrombolysis (intravenous treatment that dissolves the 
clot) and thrombectomy (mechanical removal of the clot by catheter). Thrombolysis needs to 
be given within 4.5 hours from symptom onset and only when no contraindications exist. The 
sooner the treatment is performed, the better the prognosis for the patient. Contraindications 
to thrombolysis include for example recent surgery, ongoing treatment with anticoagulants 
and intracranial haemorrhages. Studies have shown that about 20% of stroke patients could 
be treated with thrombolysis, but that the level is lower for the majority of Swedish hospitals, 
although rising (34, 42).  
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Thrombectomy is usually performed when thrombolysis is considered inappropriate or when 
the desired effect from thrombolysis is not reached (34). The use of thrombectomy in Sweden 
is increasing, although still primarily performed at three Swedish university hospitals, 
implicating unequal access to this treatment within the country (42).  
In malignant media infarction, a hemicraniectomy (surgical removal of part of the skull to 
relieve pressure off the brain) within 48 hours of onset can also be effective and has been 
shown to reduce deaths by 50% (32). This is however only relevant for a small part of the 
patient population. 
If a patient has a haemorrhage, neurosurgical treatment, such as evacuation of the hematoma, 
may be a life-saving option. In cases where the patient has been treated with anticoagulants 
prior to the bleeding, coagulants are commonly used (43). 
After acute management of the patients, the treatment focus is on rehabilitation and 
secondary prevention, often with life-long follow-up. Patients are cared for by a 
multidisciplinary team, which can include physicians, nurses, assistant nurses, occupational 
therapists, physiotherapists, social workers, speech therapists, dieticians and psychologists 
(with neuropsychological focus). The rehabilitation can for example include motor training, 
ADL-training (activities of daily living), language training and counselling regarding 
adaptation to acquired impairments in body function and activity. 
Apart from inpatient care at a stroke unit or rehabilitation centre, the stroke patients may 
receive care through early supported discharge and continued rehabilitation in the home 
setting, as well as care at specialized outpatient clinics and primary care centres (important 
for secondary prevention). Many patients also receive home care service, home help or move 
into special housing provided by the municipalities (in the case for Sweden). 
1.2.4 Treatment outcome 
Outcomes in clinical trials and measurement of effect are often focused on mortality and 
functional disability after stroke. For degree of disability or ability to perform activities of 
daily living, the Barthel Index and modified Rankin Scale (mRS) have been used most 
extensively in clinical trials, both validated for stroke (44). The Barthel Index assesses the 
patients on a scale of 0-100 where scores above 60 is considered favourable, whereas mRS 
assesses the patients functional disability on the scale 0-6 where 0 is minimal functional 
disability and 6 is dead, and 0-2 is generally considered a favourable outcome (44).  
These do not fully account for the quality of life of the patients. To assess the full 
consequences of stroke, instruments of assessing quality of life can be used as complements.  
1.3 HEALTH ECONOMICS 
Health economics has been defined as “the application of the theories, tools and concepts of 
economics as a discipline to the topics of health and healthcare. Since economics as a science 
is concerned with the allocation of scarce resources, health economics is concerned with 
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issues relating to the allocation of scarce resources to improve health. This includes both 
resource allocation within the economy to the healthcare system and within the healthcare 
system to different activities and individuals” (45). 
A related theoretical framework is value-based healthcare, where value is defined as health 
outcomes achieved per money spent (46). Value-based healthcare has its ground in 
management theories and also includes aspects of healthcare organisation in order to 
maximize the value of healthcare.  
Both frameworks have in common to put health outcomes in relation to the costs to ensure 
efficient use of limited resources. Both frameworks also put emphasis on the health outcomes 
relevant to the patients. Health economics, however, provides tools to analyse the healthcare 
system and its interventions, taking into account both health effects and costs which provides 
the main analytical framework of this thesis. 
1.3.1 Health outcomes 
Health is defined by WHO as “a state of complete physical, mental and social well-being and 
not merely the absence of disease or infirmity” (Preamble to the constitution of the World 
Health Organization, Geneva, 1948). Depending on which aspect is most relevant for the 
analyses at hand, health outcomes can be assessed in several ways. Health outcomes could be 
categorized as either hard or soft endpoints:  
Hard endpoints. These are health outcomes that can be measured objectively, for example 
mortality or incidence of cardiovascular disease. Clinical markers/endpoints can be 
considered as intermediate or surrogate endpoints for the health outcome of interest. For 
example, in diabetes, a well-maintained diabetes will decrease the risk of long-term 
complications such as cardiovascular events, although this effect is hard to assess at the time-
point of treatment. Clinical markers such as HbA1C may therefore be used instead to assess 
the health effects of a treatment. RCTs often have clinical endpoints as a measure of efficacy. 
For health economic evaluations, a transformation from these surrogate endpoints to other 
health outcomes more relevant to the patients are often necessary as these are of greater 
interest for policy decisions (47).  
Soft endpoints. These are often patient reported outcome measures (PROMs), commonly 
assessed by questionnaires that are completed by the patients. In health economics, Health-
Related Quality of Life (HRQoL) is often of great interest, taking into account several 
different aspects of effects a disease has on the patient’s health. There are several validated 
quality of life instruments developed that are used for this purpose, both disease specific 
instruments and generic instruments such as the Short Form (SF)-36 (48). There are also 
other instruments and questionnaires assessing more specific health outcomes, such as 
experienced symptoms or ability to perform specific activities. Patient reported experience 
measures (PREM) are also measures reported by the patients (sometimes in the same 
questionnaire as PROMs), where questions refer to how the patients have experienced the 
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care that they have received. PREMs are, however, usually not classified as a health outcome, 
rather as an assessment of the care process.  
In health economics, the term utility is often used when assessing the quality of life effects of 
a healthcare intervention. Utility in this setting is really a preference for a specific health 
state, expressed as a weight anchored between 0 (death or health state equivalent to death) 
and 1 (perfect health), and not a utility by its original theoretical definition. As stated by 
Drummond et al (49), preferences is by definition a broad term which includes both values 
(rational decisions under certainty) and utilities (rational decision under uncertainty). The 
measurement of preferences may be done through different methods, either scaling methods 
(e.g. rating scale or visual analogue scale [VAS]) or choice methods (e.g. time trade-off 
[TTO] or standard gamble [SG]). Only estimation by SG fulfils the original theoretical 
definition of utilities (decisions under uncertainty) as presented by von Neumann and 
Morgenstern (49), whereas the other methods results in a value. In this thesis, the term utility 
is, however, used in the commonly used broader meaning of the term. 
There are validated generic questionnaires available (such as EQ-5D or SF-6D), where 
patients answer a few questions with regards to their current health state, and the results are 
thereafter converted into a preference weight or utility for that health state. The algorithms for 
conversion of the responses to a preference weight are most often based on published studies 
where a selection of responders from the general public have judged different health states by 
one of the choice methods (TTO or SG).  
In economic evaluations, the preference weight (on the scale 0-1) is often multiplied with 
survival (life-years), resulting in a combined health outcome measure referred to as quality-
adjusted life-years (QALYs). A QALY covers both mortality and quality of life effects of an 
intervention, and one QALY is interpreted as being equivalent to one year of life in perfect 
health. QALYs are useful when health outcomes in different diseases need to be put in 
relation to each other, e.g. in decisions on resource allocation within the healthcare system to 
different diagnostic areas.  
1.3.2 Resources and costs 
Attributing costs of healthcare to a treatment or a specific disease is not straight forward. All 
relevant resources need to be translated into measurable units, such as inpatient bed days, 
outpatient visits or hours of informal care. Thereafter a unit cost needs to be defined for each 
unit of resource and multiplied with the amount of resources.  
In economic theory, the relevant cost is the opportunity cost, i.e. the benefit forgone from 
using resources for one purpose rather than in their best alternative use (45). This means that 
costs occur even in the absence of a financial flow, e.g. in the case of an informal carer. In 
practice, costing is often performed by using official price lists. 
Which costs to include in a health economic analysis should be limited to the costs 
attributable to the treatment or the disease. It will also depend on chosen perspective, i.e. if 
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the analysis takes a payer perspective (only including costs incurred by the payer) or a 
societal perspective (including all costs irrespective of who incurs them) (45). Traditionally 
the societal perspective is employed in Sweden whereas some other countries apply a 
narrower perspective, such as to only consider costs affecting the healthcare sector 
(www.ispor.org).   
Direct costs cover both medical costs such as hospitalizations, outpatient visits, procedures 
and services such as home care; as well as non-medical costs, such as transportations, home 
help, non-medical devices and informal care. Market prices are available for many of these 
resources but for some of them costing is less straight forward. For example, for informal 
care (care by e.g. relatives), the cost can be estimated based on the income lost due to the 
caregiver performing care (based on the caregivers’ wage). However, time spent by the 
caregiver is not only conducted during working hours, rather the opportunity cost should also 
cover loss of leisure time, which is generally valued below earnings. Another method is to 
use market price of a close substitute (i.e. if the care service would have been bought instead), 
referred to as the replacement cost method.  
Indirect costs refers to productivity losses incurred when patients are on sick leave, have 
reduced productivity at work, end up in early retirement or die prematurely related to the 
specific disease (45). Indirect costs are commonly priced with the human capital approach, 
which values the lost production with gross earnings (50). Critiques against this method argue 
that sooner or later the lost capacity will be replaced, and hence the productivity loss will 
diminish. A method to account for this is referred to as the friction cost method (51). Since 
indirect costs refer to lost productivity, it only incurs in the years when the patient is part of 
the workforce. In diseases with a chronic disabling condition such as RA and stroke, indirect 
costs may be substantial if onset is while the patients are still participating in the workforce. 
Intangible costs are costs related to loss in quality of life or suffering for the patient due to a 
disease or a treatment. These costs are, however, difficult to estimate and are usually included 
in the health outcomes dimension in the case of a health economic evaluation. 
Costs in added life-years appears when an intervention prolongs the life of patients as the 
increased survival also can be associated with a cost to society, that is not directly related to 
the treatment or disease evaluated. This cost represents the difference in consumption and 
production over the gained number of life years. Individuals over retirement age most often 
consume more resources than they produce, while younger produce more than they consume 
(52, 53).  
In cases where treatment prolongs life but does not keep patients in the workforce, the 
inclusion of indirect costs and cost in added life years only adds to the cost of keeping 
patients alive. This may be problematic from an ethical point of view as it can discriminate 
patient groups far from the workforce if the analysis is used for decision making. More recent 
recommendations by the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden 
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therefore suggest that in these circumstances, the indirect costs and costs in added life years 
may be omitted from the analysis (www.tlv.se).  
1.3.3 Health economic analyses 
Health economic analyses are studies which consider both health aspects and costs (or 
resources). Broadly, health economic analyses can either be an economic evaluation of a 
specific intervention or a burden-of-illness study which attempts to assess the total burden of 
a disease on a society.   
Economic evaluations 
An economic evaluation has been defined as “the comparative analysis of alternative course 
of action in terms of both their costs and consequences” (54). Economic evaluations give 
information on a treatment alternative compared to (at least) one other alternative, which may 
serve as basis for decisions of resource allocation within the healthcare system.  
The term cost-effectiveness analysis is often used to describe the economic evaluation at 
hand. However, there are different types of economic evaluations which are dependent on 
how the health outcome (effect) is assessed: 
• Cost-minimization analysis (CMA): when the treatment options have equal effects 
and only costs are compared 
• Cost-effectiveness analysis (CEA): when outcome is one-dimensional, e.g. life-years 
gained, events avoided 
• Cost-utility analysis (CUA): when outcome is two-dimensional, e.g life-time gained 
and quality of life combined into QALYs 
• Cost-benefit analysis (CBA): when outcome is measured in monetary terms 
The most common type economic evaluation is the CEA or CUA. The results of these 
analyses are presented as an incremental cost-effectiveness ratio (ICER), which is defined as 
the incremental cost (C) divided by the incremental effect (E) of one intervention (A) 








The ICER is interpreted as the incremental cost to gain an extra unit of health outcome, for 
example the cost per life-year gained. Whether a result is to be considered cost-effective or 
not will depend on the willingness to pay (WTP) for an additional unit of health outcome. In 
Sweden for example, cost-effectiveness analyses are performed for new pharmaceuticals and 
submitted to TLV for reimbursement approval. One of the criteria for the decision is cost-
effectiveness, and TLV will in their decision compare the ICER and the uncertainty around 
this estimate to the WTP. The WTP is not at a fixed level, it rather tend to be higher for more 
severe diseases such as cancer, but has historically been around €65,000/QALY gained (55). 
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Economic evaluations often need to combine data from several sources, e.g. clinical trials, 
registers, observational data and other published data on resources, costs and outcomes. 
Additionally, data may only be available for a short follow-up (e.g. in the case of RCTs) and 
there may be a need for extrapolation over time. Models, defined as “mathematical 
frameworks that facilitate estimation of the consequences of healthcare decisions” (56), are 
useful in economic evaluations, enabling all relevant costs and consequences to be taken into 
account. A model is a simplification of reality where the course of the disease and the main 
effects of the treatment are mirrored. The choice of modelling technique or software does not 
matter to the results as long as all relevant costs and effects are included and the model is 
structured in a correct manner. The choice of model should be based on what is most 
appropriate for the disease and course of action of the treatment, as well as data availability.  
For example, a decision tree model (see Figure 4) is a simple form of model, suitable for 
analyses with a short-term horizon or when the possible number of outcomes is limited. In 
this example, there is one treatment arm and one comparator arm, where the patient can either 
get cured or die. For each choice, the treatment (treatment arm) is compared to no treatment 
(comparator arm), all costs and effects (proportion cured) are summarized at the end of the 
tree and compared to each other.   
 
 
Figure 4. Decision tree model 
In economic evaluations, however, more advanced models are most often necessary and 
different models holds different attributes which makes them more or less suitable for the 
analysis at hand. A summary of the main model types, their attributes and where the models 
are most suitable are listed in Table 1. 
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Table 1. Summary of main model types 




1. Cohort model or 
“Markov model” 
2. Individual based 
model or “first-
order Monte Carlo” 
or 
“micorsimulation” 
States – a condition an individual 
can be in. All states are mutually 
exclusive and collectively 
exhaustive 
Transitions – how the 
cohort/patients move among states 
Transition probabilities – how 
likely these moves are 
Cycle – time interval when 
transitions are possible 














Entities – are the objects, in 
healthcare mainly patients 
Attributes – features specific to 
each entity to carry information 
(e.g. risk factors, QoL), can be 
modified over time 
Events – things that can happen to 
the entity. These are mutually 
exclusive (discrete) 
Resource - an object that provides 
service to an entity, can be 
“occupied” which creates queues. 
Time - Model jumps from the time 
of one event to the time of the next 
In cases where patients 
are subject to multiple 
or competing risks and 









Any sub-type possible, 
e.g.: 
• Deterministic or 
stochastic 
• Individual or cohort 
based 
Dynamic function of risk, taking 
into account number of infectious 
individuals in the population at a 
given point in time 
Suitable when 
evaluating an 
intervention against an 
infectious disease that:  
• impacts a pathogens 
ecology or 





The choice of subtype of a model may come down to convenience. For example, a cohort 
simulation STM should be chosen if the decision problem can be represented with 
manageable number of health states that can incorporate all characteristics that are relevant to 
the decision problem. If instead the representation ends up with an unmanageable number of 
states, then an individual level STM is preferred, although such model in general is more 
complex and less transparent (57).  
A STM is often illustrated in a state transition diagram where the arrows indicate all possible 
transitions from one state to another (or possibility of remaining in current state) (Figure 5). 
Dead is always an absorbing state where the patients remain throughout the simulation. Each 
health state is associated with a cost and a health effect and at the end of the simulation (e.g. a 
pre-defined timeframe of 20 years), all costs and effects for the comparing alternatives are 
summarized. 
 
Figure 5. STM model state transition diagram 
Burden-of-illness   
Burden-of-illness analyses (or commonly referred to as cost-of-illness when expressed in 
monetary values) are not designed to assess specific interventions, rather estimate the burden 
a specific disease has on society. As these studies do not assess the effect on health outcomes 
by an intervention, it is not an economic evaluation and cannot demonstrate where resources 
should be allocated to improve health outcomes. These studies can, however, inform policy 
makers on the burden or severity of a disease, which can be useful in planning and making 
budget decisions and decisions on resource allocation within the economy, as well as serve as 
input data in specific economic evaluations (45). Burden-of-illness methodology covers 
direct, indirect and intangible costs related to a disease. However, the latter is commonly not 
translated into monetary values, but rather expressed as quality of life, QALYs or Disability-
Adjusted Life-Years (DALYs) (60). Direct and indirect costs can also be expressed either as 
amount of resources utilized or in monetary terms.  
In a prevalence based approach, all cost items for a disease in a given geographical area is 
collected for a specific time-period, covering all patients with the specific disease. In an 
incidence based approach, on the other hand, estimates cover the time from diagnosis to cure 
(or death in the case of chronic diseases) (45). Results from these studies are often presented 
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on a total population basis, but can also be presented on a per-patient basis or separated for 
specific sub-groups of patients.   
Further, method chosen to do a burden-of-illness study can be top-down or bottom-up. In a 
top-down study e.g. a register may be used to estimate the costs for a given sample of 
patients. Using a bottom-up method, all costs would instead be collected directly from the 
patients, either from questionnaires retrospectively or following the patients prospectively for 
a given time. The top-down method may underestimate the burden when not all information 
is available in public records but it is a method which is relatively time efficient and allows 
for inclusion of large datasets. A bottom-up method on the other hand is more costly and 
time-consuming and puts higher emphasis on ensuring that the patient sample is unbiased and 
representative to be able to draw general conclusions, although allowing for a more coherent 
coverage of resources or health outcomes (45). 
1.4 PREVIOUS STUDIES BASED ON SWEDISH QUALITY REGISTER DATA 
Quality registers in Sweden are used for many scientific purposes and many papers have been 
published based on the data. However, their use in health economic analyses has been more 
limited, although usage for these purposes has increased in later years. A selection of health 
economic analyses based on Swedish quality register data covering patients with RA or 
stroke are listed in Table 2. These either uses methodology of economic evaluations or 
burden-of-illness analyses, where the latter either assessed indirect costs, direct costs or both 
(expressed either in resources/productivity loss or costs). Furthermore, Swedish quality 
register data has also been used in health economic analyses of diabetes (61-64), MS (65, 66) 
and cancer (67-71), among other diseases, however omitted from this summary. 
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Table 2 Selected health economic analyses based on Swedish quality register data for patients with RA or stroke 




Eriksson et al (72) Cost-effectiveness of infliximab versus conventional combination treatment in 
methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-
enriched randomised controlled SWEFOT trial. 
2015 SRQ Economic evaluation: CUA 
Kobelt (73) Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose 
reductions when remission is achieved 
2014 SRQ Economic evaluation: CUA 
Lindgren et al (74) Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab 
using registry data from Southern Sweden 
2009 SRQ (SSATG) Economic evaluation: CUA 
Neovius et al (75) Sick leave and disability pension before and after initiation of antirheumatic 
therapies in clinical practice. 
2011 SRQ BOI: Indirect cost  
Neovius et al (22) How large are the productivity losses in contemporary patients with RA, and how 
soon in relation to diagnosis do they develop 
2011 SRQ BOI: Indirect cost 
Augustsson et al (76) Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists 
increase their participation in the workforce: potential for significant long-term 
indirect cost gains (data from a population-based registry) 
2010 SRQ (STURE) BOI: Workforce participation 
Kobelt et al (77) Costs and outcomes for patients with rheumatoid arthritis treated with biological 
drugs in Sweden: a model based on registry data. 






Steen Carlsson et al (78) Long-term cost-effectiveness of thrombectomy for acute ischaemic stroke in real 
life: An analysis based on data from the Swedish Stroke Register (Riksstroke) 
2017 Riksstroke Economic evaluation: CUA 
Sunnerhagen et al (79) WebRehab: a Swedish database for quality control in rehabilitation 2014 WebRehab BOI: Direct costs 
Gathnekar et al (80) Costs for stroke in Sweden 2009 and developments since 1997 2014 Riksstroke BOI: Direct & indirect costs 
Persson et al (81) Economic burden of stroke in a large county in Sweden 2012 Riksstroke BOI: Direct & indirect costs 
Gathnekar et al (82) The effect of Atrial Fibrillation on Stroke-Related Inpatient Costs in Sweden 2008 Riksstroke BOI: Direct costs 
Lindgren et al (83) Utility loss and indirect costs after stroke in Sweden 2008 Riksstroke BOI: Indirect costs  
Gathnekar et al (7) Cost of stroke in Sweden: An incidence estimate 2004 Riksstroke BOI: Direct & indirect costs 
BOI = Buren-of-illness
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1.4.1 Economic evaluations 
Three articles investigated the cost-utility of different treatment alternatives for RA, based in 
part on data from the SRQ. The first article, by Lindgren et al, modelled the cost-
effectiveness of Rituximab as second-line biological treatment (74), utilizing data from SRQ 
(different parts of the register) for identifying the study cohort, retrieving patient 
characteristics (e.g. gender, age, years since diagnosis, disease severity) as well as the 
estimated effectiveness of the treatments modelled based on functional capacity (HAQ) and 
disease activity (DAS28) scores. The second study, by Kobelt et al (73), estimated cost-
effectiveness of dose reduction of anti-TNF treatment when remission is achieved (three 
different strategies), where “standard therapy” after failure of the intervention therapy being 
discontinued was taken from SRQ, i.e. the transition probabilities after treatment failure for 
up to 10 years. The third study, by Eriksson et al (72), evaluated the cost-effectiveness of 
infliximab use compared to conventional therapy in patients with MTX-refractory early 
rheumatoid arthritis, based on the SWEFOT clinical trial, using data from SRQ for assessing 
drug use for costing purposes (not effectiveness).  
The study evaluating Rituximab found this therapy to be a cost-saving alternative to anti-TNF 
treatment after failure of the first anti-TNF treatment (74). In the study on dose reduction, the 
strategy of dose reduction of anti-TNF therapy while in remission was found most 
advantageous from a health economic perspective (73). The study in early MTX-refractory 
RA-patients, infliximab therapy was not found to be cost-effective over a 21-month period 
(72). Other studies evaluating biological treatments for RA in clinical practice in other 
countries have reached similar conclusions as in these studies (84-86).  
One recent article with a cost-effectiveness focus on stroke treatment was identified, 
evaluating the cost-effectiveness of thrombectomy after thrombolysis (78). This study by 
Steen Carlsson et al (78) used data from Riksstroke on the need for healthcare and social 
services for patients with severe ischemic stroke, stratified by age and mRS-status. 
Effectiveness data were retrieved from clinical trials. The results indicated that thrombectomy 
was cost-saving when accounting for the costs saved in the social service sector. 
Additionally, in an article by Ghatnekar, a cost-effectiveness assessment of admission to 
stroke unit was performed as part of a study, indicating reasonable levels of cost per life years 
gained (<€20,000). This assessment was based on data from Riksstroke to identify the cohort, 
patient characteristics, resource use, living conditions, functional ability (ADL) and 
admission to stroke units. 
Cost-effectiveness analyses have also been conducted on thrombolysis based on clinical trial 
data, where data on outcome and costs has been retrieved from patient registers in a UK 
setting (87). The number of such analyses is today scarce, however expected to increase as 
these therapies becomes more common in clinical practice and longitudinal data becomes 
available for example in Riksstroke.  
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1.4.2 Burden-of-illness analyses 
Four studies have used data from SRQ for estimating different cost-components of RA. Two 
articles by Neovius et al (22, 75) were tightly linked, one estimating sick leave and disability 
pension in patients diagnosed with early RA (22) and the other investigating sick leave and 
disability pension among patients with RA in relation to initiation of biological and non-
biological therapies (75). The outcome of sick leave and disability pensions were retrieved 
from Swedish Social Insurance Agency (Försäkringskassan) in both studies and SRQ was 
used to identify the patient cohort as well as in retrieving patient characteristics. Both studies 
indicated that productivity losses increased the years before diagnosis and before initiation of 
antirheumatic therapies (22, 75). Treatment initiation halted this development of increase in 
productivity losses although it did not reverse it. In a study by Augustsson et al (76), these 
findings were further confirmed as it showed that initiation of biological therapy increased 
workforce participation. This study used data from the SRQ for cohort identification and 
patient characteristics, but also used the information on workforce participation as collected 
within the Stockholm part of SRQ (STURE database). However, indirect costs as a 
consequence of RA were not estimated. Kobelt et al (77) investigated costs and outcomes for 
RA patients treated with biological treatment. The analysis was based on data from SRQ for 
identifying the patient cohort and patient characteristics, but also outcomes on HAQ and 
linking this to cost estimates. Resource consumption was based on a survey. This study 
estimated both direct and indirect costs of RA as well as determinants of resources use, which 
were found to be sensitive to functional capacity at treatment initiation (HAQ), disease 
progression, age and disease duration.  
Further, in a study by Kalkan et al (88), a shift in cost composition over time for patients with 
RA in Sweden was indicated, where the cost of biological DMARDs has increased whereas 
costs for inpatient care and indirect costs have decreased. This was a Swedish register based 
study, although no data from a quality register was used in this assessment. 
The cost-estimates from the two studies presented in Table 3 indicated similar levels for 
indirect costs in a Swedish setting, when taking different time horizons, cohorts and different 
methods for estimations (register versus survey) into account. 
Table 3 Cost estimates of RA 
Study Details Direct costs Biological 
treatment 
Indirect cost Year of 
prices 
Neovius et al 
(22) 
1 year cost, excess 
productivity loss 
  92,000 SEK 2007 
Kobelt et al 
(77) 
Start HAQ 1.33, 
5 year horizon 
200,000 SEK  
(40,000 
SEK/year) 
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Riksstroke has been used for several assessments of cost-components of stroke. Three articles 
by Ghatnekar et al (7, 80, 82) and one by Lindgren et al (83) have used Riksstroke for 
identifying the cohort and determining patient characteristics. In a cost assessment by 
Ghatnekar (80) comparing the cost of stroke in Sweden 2009 to 1997, the cost estimates were 
based on resource use as measured in Riksstroke at admission, after three months and after 
twelve months. The study had a societal perspective. In another study by Ghatnekar (7), data 
for resource use was instead retrieved from the national patient register, although the cohort, 
patient characteristics and need for assistance were still based on Riksstroke. As the second 
study had access to the total amount of healthcare resources used by the patient (inpatient and 
outpatient visits) whereas the first only had what was registered in the acute forms from 
Riksstroke, the direct costs were estimated to be higher in the second study whereas the 
estimates for indirect costs reached similar levels in both studies. 
The effects of determinants of cost estimates were investigated in the third study by 
Ghatnekar et al (82), concluding that strokes related to atrial fibrillation (AF) were associated 
with higher costs than non-AF related strokes. These findings were based on patient 
characteristics and cohort selection from Riksstroke whereas resource use was estimated 
based on the national patient register. The study by Lindgren et al (83) used a survey to 
estimate the productivity losses due to stroke, based on a cohort from Riksstroke. In Persson 
et al (81), the economic burden of stroke in one Swedish region was estimated, using macro 
data from Riksstroke on municipality care and informal care, presenting the excess costs both 
separately for the first three years and as expected life-time costs. 
In all, the estimates of indirect costs in the different studies were in line with each other, 
although the level of costs was set at different years. For direct costs the comparison is not as 
straight forward as the different articles have different time horizons, methods for estimation 
and inclusion of cost-items (see Table 4). Two additional Swedish studies (89, 90) based on 
register data (although not containing data from a quality register) found the costs to be in 
line with the findings of Persson et al (81). 
In an article by Sunnerhagen et al (79), the WebRehab quality register was used, assessing 
length of stay for patients at rehabilitation clinics, among those patients with stroke. Out of 
those admitted, stroke patients had on average 37 days in rehabilitation clinic. It should be 
noted that this is only a subset of the total stroke population.  
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Table 4 Cost estimates for stroke 
Study Cost horizon Direct Costs Indirect Costs Year for price 
Ghatnekar et al 2014 (80) Life-time €54,000 €14,500  2009 
Ghatnekar et al 2004 (7) Life-time €60,800 € 14,800  2000 
Ghatnekar et al 2008 (82) 3-year €9,000  2001 
Persson et al 2012 (81) First year €17,0002 €4,0002 2008 
Hallberg et al 20161 (89) First year €10,000  2012 
Banefeldt et al 20161 (90) First year  €6,800 2012 
Lindgren et al 2007 (83) First year (<65)  €13,200  2006 
1. Register data but not from a quality register, only county council resources, Banefeldt et al only for working 
age;  
2. Approximation from graph 
1.4.3 Knowledge gaps 
Most studies using quality registers for health economic purposes in Sweden have used them 
primarily to identify the patient cohort and retrieve information on patient characteristics. For 
both RA and stroke, there is a potential to further utilize the data available within the quality 
registers for health economic purposes. Specifically, there is an opportunity to increase the 
knowledge in: 
• Estimating the cost-effectiveness in clinical practice of different treatment alternatives 
and how these compare to clinical trials. 
• Estimating health outcomes and relating them to resources and costs  
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2 AIMS OF THESIS 
The overall aim of this thesis was to study the applicability of data from quality registers in 
health economic analyses of chronic conditions. The specific aims were: 
• To assess the applicability of data from a quality register in economic evaluations of 
anti-TNF treatment in clinical practice for rheumatoid arthritis 
• To assess the applicability of data from a quality register in burden-of-illness analyses 
where health outcomes, resource use and costs of stroke are put in relation to each 
other 
All papers of this thesis were based on quality register data to assess different health 
economic aspects. The different papers have the following specific aims, all for the Swedish 
setting: 
I. To estimate the cost-effectiveness of infliximab use in patients with rheumatoid 
arthritis in clinical practice. 
 
II. To estimate the cost-effectiveness of anti-TNF therapy for the treatment of 
rheumatoid arthritis in clinical practice, both as a first and second biological 
treatment, with or without the combination of conventional DMARDs. 
 
III. To evaluate the precision of the predictive cost-effectiveness assessment based on a 
phase 3 clinical trial with infliximab for the treatment of rheumatoid arthritis in 
clinical practice. 
 
IV. To estimate the level of health outcomes and resource use on hospital level during the 
first year after stroke, and to analyze any potential differences between hospitals after 
adjusting for patient characteristics (case-mix adjustment). 
 
V. To estimate the costs of stroke care by level of disability and stroke type.  
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3 MATERIALS AND METHODS 
3.1 RHEUMATOID ARTHRITIS COHORT 
The cohort of patients with rheumatoid arthritis was taken from the SRQ for papers I-III. In 
paper III, an additional cohort of patients was identified from the phase III ATTRACT trial 
for infliximab therapy.  
3.1.1 Swedish Rheumatology Quality Register (SRQ) 
The SRQ collects data on patient reported health status, clinical and laboratory data as well as 
information on treatments received. Biological treatments have been monitored on a national 
level in SRQ since their introduction in 1999. SRQ is a network of several registers, together 
providing national coverage of approximately 80% of all RA patients (www.srq.nu) (91).    
Patient level data was retrieved from three data sources that are part of the SRQ. Data from 
the Stockholm TNF-alfa Follow-up Registry (STURE) was used for papers I-III. In addition, 
paper II included data from South Swedish Arthritis Treatment Group register (SSATG) and 
the Falun section of SRQ, providing a wider geographical spread across the country in the 
patient cohort. Because data from the first introduction of anti-TNFs on the Swedish market 
was available, it was possible to classify patients according to their first- or second-line 
biological DMARDs (anti-TNF therapy). The SRQ includes only a limited number of 
patients without biological DMARDs, and a comparison to a population without biological 
DMARD was hence not possible based on quality register data. 
The full dataset for papers I-III consisted of patients initiating treatment with any anti-TNF 
treatment between 1998 and 2008, constituting approximately 90 % of all RA patients treated 
with biologics in the regions covered for the specific time-period.  
3.1.2 ATTRACT trial 
The ATTRACT trial was the pivotal RCT where patients were randomized to infliximab plus 
MTX or to placebo plus MTX, receiving treatment every 8 weeks for 1 year. The double-
blinded period was followed by an open extension (92, 93).  
Aggregated data from the ATTRACT trial was used in paper III. 
3.1.3 Study populations and variables 
The study population in paper I consisted of 637 patients receiving infliximab therapy as their 
first-line biological therapy, from the STURE part of the SRQ. 
The study population in paper II consisted of 2,558 patients receiving any anti-TNF therapy 
as their first-line biological treatment, from the STURE, SSATG and Falun part of the SRQ.   
In paper III, three cohorts were identified, where the first two were elicited from the study 
population in paper I: 
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1. All patients receiving infliximab therapy as first-line treatment (637 
patients) from the STURE part of SRQ. 
2. All patients receiving infliximab therapy as first-line treatment from the 
STURE dataset, and who met the RCT inclusion criteria (306 patients, 48% 
of the STURE dataset).   
3. Patients in the ATTRACT trial randomized to infliximab therapy (287 
patients) or placebo (58 patients). 
Data on disease progression over states of HAQ and DAS28 during treatment, treatment 
regimen, line of biological treatment as well as discontinuation rates from the SRQ dataset 
were used for papers I, II and III.  
Data on patient characteristics, effectiveness (HAQ and DAS28 transitions) and treatment 
discontinuation was retrieved from the ATTRACT trial on aggregated level for paper III. 
3.2 STROKE COHORT 
The patient cohort for papers IV and V was retrieved from the quality register Riksstroke and 
the patient administrative systems of seven Swedish regions. This was complemented with 
data from several other Swedish national registers.  
3.2.1 Swedish Stroke Register (Riksstroke) 
The Swedish Stroke Register (Riksstroke) is the national quality register for stroke care, 
monitoring patients with IS, ICH or unspecified stroke as well as patients with TIA. Patients 
with SAH are not included in the register. The register entails, among other, information on 
acute treatment, first admission to hospital, secondary prevention, PROMs and PREMs. The 
registry collects data at admission for acute stroke and after three and twelve months, 
respectively. All hospitals admitting patients with acute stroke collects and reports data to 
Riksstroke. The national coverage of the acute form has been estimated to 96% after 
validation when compared to the national patient register (34). The coverage for the three and 
twelve months’ forms are estimated to be 88% and 81%, respectively, out of those with an 
acute form in Riksstroke and who are still alive at time of follow-up (www.riksstroke.se). The 
form at admission and three months are completed by the treating clinic (including patient 
interview or questionnaire for the PROM and PREM measurements) whereas the form at 
twelve months is sent out to the patients from Riksstrokes central administration.  
Patient level data was retrieved from Riksstroke, consisting of all patients with an acute 
stroke (IS or ICH) registered in Riksstroke between 2007 and 2012 in any of the following 
Swedish regions: Jämtland Härjedalen (RJH), Östergötland (RÖ), Dalarna (LtD), Uppsala 
(LUL), Skåne (RS), Stockholm (SLL), and Västra Götaland (VGR). The included regions 
were those participating in the Sveus research program (www.sveus.se). This selection covers 
approximately 60% of all strokes annually in Sweden.  
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Data on patient characteristics and health outcomes (PROMs) for this study population was 
used in papers IV and V.  
Functional ability was assessed through mRS, and good functioning was defined as mRS 0-2. 
Riksstroke does not collect mRS but contain variables that enables an estimation of mRS at 
three and twelve months post stroke, based on algorithms validated by Eriksson et al (94). 
3.2.2 Patient administrative systems (PAS)  
Each region in Sweden has a patient administrative system which collects data on all 
healthcare contacts a patient has, including date of visit or admission, diagnosis and 
procedure codes (ICD-10 and KVÅ, respectively) as well as information about the hospital. 
Data from seven Swedish regions (RJH, RÖ, LtD, LUL, RS, SLL and VGR) was used. PAS 
has practically complete coverage, although there is a varying quality in registration of 
diagnosis and procedure codes in these registers.  
Data was retrieved from the regions on all adult patients (>18 years) with an acute stroke 
diagnosis, defined by ICD-10 codes I61* for ICH and I63* for IS as main diagnosis in the 
time-period from 2007 to 2012. All data for these patients during this time period was 
extracted and the individuals were linked to data retrieved from Riksstroke. Data on 
healthcare contacts, procedure codes and comorbidities was used for paper IV and V. 
3.2.3 LISA database 
Statistics Sweden (SCB) collects population based data which can be used for research 
purposes. From the LISA database (Longitudinal integration database for health insurance 
and labour market studies), information on each individual’s socioeconomic status can be 
retrieved. The database presently holds annual registers since 1990 and includes all 
individuals 16 years of age and older who were registered in Sweden as of 31st of December 
for each year. The database integrates existing data from the labour market, educational and 
social sectors and is updated each year with a new annual register.  
Data on socioeconomic factors was linked on individual level to the study population of 
stroke patients. Data on socioeconomic status was used in paper IV to allow for case-mix 
adjustment. 
3.2.4 Total population register 
Statistics Sweden keeps information on date of death as part of the total population register 
(RTB). This information was linked on individual level to the study population, and used in 
papers IV and V. 
3.2.5 Care and social services for the elderly and for persons with 
impairments (SoL) 
The SoL register is administered by the National Board of Health and Welfare 
(Socialstyrelsen). The register contains information on individual level on the scope of 
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municipal services in accordance with the Social Services Act (2001:453), provided for 
elderly and persons with functional impairments. 
Data on special forms of housing (measured in days for paper V and proportion moving into 
special housing in paper IV) and home care services (measured in hours) was linked on 
individual level to the stroke study population and used in paper IV and V.  
3.2.6 MiDAS database 
The MiDAS database is administrated by the Swedish Social Insurance Agency 
(Försäkringskassan) and contains information on individual level about sick leave (after first 
two weeks of absence), rehabilitation support and disability pensions / early retirement.  
Data on sick leave (measured in net days) and disability pensions / early retirement 
(measured in net days) was linked on individual level to the stroke study population and used 
in papers IV and V. In paper IV this information was used as a health outcome indicating the 
proportion of patients who were working full time after one year, as a proxy for regaining 
work ability, whereas in paper V it is assessed as a resource in days of work absence.  
3.2.7 Study populations and variables 
The final study population for paper IV and V consisted of patients registered both in PAS 
and Riksstroke, linked to each other and other register sources through the unique Swedish 
personal identification numbers. Data linkage and de-identification of the dataset was 
performed by Statistics Sweden. Extensive data management was performed to ensure 
consistency between the data from the different PAS systems and identification of variables 
necessary for the analyses in papers IV and V.  
Patients residing in another region than the seven included regions in study IV and V were 
excluded from the analysis to allow for complete follow-up (although the initial stroke care 
was received in one of the included regions). The final study populations for each study were: 
• The study population for paper IV consisted of 14,125 patients acquiring a stroke (IS 
or ICH) during 2010, allowing inclusion of two years of history (enabling case-mix 
adjustments) and two years follow-up (only one-year results presented in paper IV).  
• The final study population for paper V consisted of 47,807 patients diagnosed with a 
stroke (IS or ICH) during 2007-2010, allowing for two years follow-up.  
A summary of the study variables from each register for papers IV and V are listed in Table 
5. Baseline characteristics in paper IV were used for case-mix adjustment of the results 
whereas in paper V they are used to stratify the patient population (by stroke type and age) 
and to give descriptive data of the study population. 
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Table 5. Study variables for paper IV and V 
  Paper IV Paper V Register source 
    
Baseline characteristics    
Stroke type X X PAS 
Age X X PAS 
Sex X X PAS 
Level of education X  LISA 
Born outside the EU X  LISA 
Single household X  Riksstroke 
Living arrangements X X Riksstroke 
ADL dependency prior to stroke X X Riksstroke 
Prior stroke within 2 years X X PAS 
Atrial fibrillation and/or hypertension 
diagnosed within last 2 years X  PAS 
Level of consciousness at arrival to 
hospital X  Riksstroke 
    
Health outcomes    
Survival  X X RTB 
Recurrent stroke X  PAS 
Functional disability (mRS) X1 X Riksstroke 
Good general health X  Riksstroke 
Work ability X  MiDAS 
    
Resources    
Inpatient bed days X X PAS 
Outpatient visits, speciality care X X PAS 
Outpatient visits, primary care X X PAS 
Home care service (hours) X X SoL 
Special housing X2 X3 SoL 
Work absence (days)  X MiDAS 
ADL dependency is defined as being dependent on help with dressing and/or going to the toilet.  
1. good outcome; 2. proportion moved into special housing; 3. days 
3.3 METHODS 
3.3.1 Health economic analyses 
Papers I-III were designed as economic evaluations where cost-utility analyses were 
performed. In order to enable combination of several data sources and projecting the long-
term cost-effectiveness of treatments for RA, Markov cohort models were used. In paper I, a 
Markov cohort model was developed and analyses performed on one first-line biological 
treatment alternative compared to no treatment. In paper II, the model was further developed 
to include several treatment options as first-line biological treatment, but also include second-
line treatment options. In paper III, a comparison between different patient populations and 
data sources (register vs RCT) was conducted, putting larger emphasis on methods of 
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matching patients and the impact of assumptions made in the model and in relation to the 
data.  
Papers IV-V were designed as burden-of-illness studies using an incidence based approach, 
estimating the burden bottom-up based on register data from multiple data sources. In paper 
IV, health outcomes and resources were defined in measurable units and advanced statistical 
analyses were performed to assess any differences between hospitals, after adjusting for 
patient mix. This paper is not a classical burden-of-illness study, although the components 
measured are part of this methodology. The way the results are presented may be considered 
closer to the framework of performance measurement, where the indicators of interest usually 
are structure, process or outcome indicators (95). However, for this thesis, the aspects closer 
to health economic theory are in focus instead. In paper V, the costs were estimated from the 
identified resources, and summarized by functional disability and stroke type, allowing for 
use of the results in future health economic evaluations.  
3.3.2 Markov models 
A Markov cohort model was developed for enabling cost-effectiveness analyses in papers I-
III. The model was based on earlier models of infliximab (93) and etanercept treatment (96), 
adapted to accommodate register data and including a second-line biological treatment option 
as in paper II, as well as allowing for comparison between more than two treatment options.  
Health states in the model were stratified over five mutually exclusive states of functional 
status (measured with HAQ), each separated into two states of disease activity (high/low, 
measured with DAS28). The cut off points for the HAQ states were 0.6; 1.1; 1.6 and 2.1 
whereas the cut-off for high disease activity was set at DAS28>3.2. The model had a long-
term horizon (20 years) and the cycle length was set to 1 year. In each cycle, patients could 
continue or discontinue treatment, remain in their current health state, transit to adjacent 
health states or die (see Figure 6). The model had in all 15 possible health states (plus dead). 
 
 Figure 6. Simplified model structure used in paper I-III 
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The transition probabilities in the comparator arm, that is disease progression without 
biologic treatment, as well as mortality rates, costs, and utilities were based on published 
literature. The analyses had a societal cost perspective including both indirect costs and cost 
in added life-years as recommended for Swedish reimbursement submissions at the time of 
this study. 
For paper III, three patient cohorts were identified and included in the model: the patients 
included in the infliximab trial (ATTRACT), patients initially treated with infliximab and 
registered in SRQ (Stockholm) and a subset of these register patients meeting inclusion 
criteria for the ATTRACT trial. The two data sources (trial vs register) had different 
characteristics in relation to efficacy data as they had different time-horizons (duration of trial 
vs data over 10 years) and possibility of comparators (placebo vs “no treatment”), imposing 
different needs of assumptions for enabling the economic evaluation. Two sets of 
assumptions were therefore applied in the model on each of the three cohorts (Table 6). 
Table 6. Model assumptions related to effect data 
 Assumptions made in the Markov model 
Aspect ATTRACT assumptions 
(RCT data) 
STURE assumptions  
(Register data) 
Comparator Placebo arm of the trial HAQ progression on standard 
therapy from published literature 
(0.065 HAQ/year) 
Discontinuation of treatment All patients discontinue 
treatment after 1 year 
Continuous discontinuation 
function based on observed 
discontinuation rates in the 
register 
Reverting to baseline HAQ at 
discontinuation of treatment 
Assumed Not assumed 
All results for studies I-III were presented as ICERs, interpreted as cost per QALY gained, 
and extensive sensitivity analyses were performed to assess the uncertainty in assumptions 
made and uncertainty in the underlying data. Both deterministic and probabilistic sensitivity 
analyses (PSA) were performed. In the PSAs, 1,000 runs were performed to assess the 
precision in the estimates. Dirichlet distributions were assigned to the HAQ transitions in the 
initial year as it is suitable to estimate the uncertainty in probabilities when using rival events 
(five mutually exclusive HAQ events in the model), and beta distributions were assigned to 
the DAS28 transitions as it is suitable when using probabilities between 0 and 1. 
The software TreeAge was used for modelling in papers I-III. 
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3.3.3 Statistical analyses 
In papers I-III, a regression function based on the RA-register dataset was implemented in the 
Markov model to assess the probability of discontinuing treatment each year (i.e. in each 
cycle in the model). The probability of discontinuing treatment with any anti-TNF therapy 
was higher in the initial year of treatment than in subsequent years, irrespective of whether it 
was taken as a first or second biological treatment. The discontinuation function was 
therefore separated into two parts in the model to get a better fit to the data; a logistic function 
for the first year and a Weibull survival function for subsequent years.  
The probability of discontinuing therapy increased with VAS pain at baseline (first biological 
in first year), HAQ at baseline (first biological in subsequent years), initiating treatment with 
an anti-TNF therapy after 2003 (first biological in first year), age at disease onset (second 
biological in first year) and DAS28 at baseline (second biological in subsequent years), which 
were accounted for in the model. 
In paper IV, an adjustment of differences in health outcomes and resource use was employed, 
using a multivariable fixed-effects regression model adjusted for clustering of patients within 
clinics. Logistic regression was performed for dichotomous outcomes, while continuous data 
was analysed using ordinary least squares (OLS) regression. The models included predictors 
of sociodemographic factors, health profile at baseline and stroke characteristics. The case-
mix adjusted results indicate the hospital effect on each dependent outcome (referred to as 
adjusted results). 
The software STATA 13.0 was used for statistical analyses. 
3.3.4 Costing 
None of the registers used for this thesis provided data on costs, but rather on resources. For 
cost estimations, necessary for papers I, II, III and V, each unit of resource was multiplied by 
a unit cost.  
In papers I-III, cost of treatment was estimated by using the unit costs for the anti-TNF 
therapies from the Swedish Pharmacy List prices (FASS) as well as cost of administration in 
the case of infliximab therapy. Other direct and indirect costs in these papers were based on 
published literature (53, 96).  
In paper V, the direct and indirect costs of stroke were estimated. The unit costs of inpatient 
stay and outpatient visits in specialist care were retrieved from the cost-per-patient (KPP) 
database at The Swedish Federation of County Councils (SKL) (97). First-year cost of 
inpatient care (per day) was identified from the KPP-database for patients with main 
diagnosis ICD-10 I61* and I63*, for ICH and IS respectively. Unit costs of inpatient care 
during second year as well as unit costs for outpatient visits both years were estimated by an 
unweighted average of daily cost in a general ward, acute care, palliative care, internal 
medicine, stroke care, geriatric care and rehabilitation. The cost of primary care visits was 
estimated by an average of available regional price lists, using rates for medical doctors and 
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other healthcare professionals respectively. Home care services and cost for special housing 
were retrieved from the cost-per-user (KPB) database at SKL (98). An unweighted average 
cost of the reporting municipalities was used. 
Indirect costs were estimated based on days of absence from work, defined as either on sick 
leave or with disability pension, using a human capital approach (50). The cost of work 
absence was estimated based on average monthly wage of all sectors, published by Statistics 
Sweden, plus employer taxes. 
3.4 ETHICAL CONSIDERATIONS 
The studies have been approved by the regional ethical committee board at Karolinska 
Institutet, Stockholm (dnr 2008/352-31 for the studies on RA and dnr 2013/1541-31/5 for the 
studies on stroke). 
Register based studies contain sensitive data on patients’ health and well-being. In these 
studies, only de-identified data (without personal identification numbers) was accessible and 
the data was kept in a secure setting. Furthermore, data is only presented on aggregated level 
to ensure that patients are not identifiable in the presented results. The potential harm on 
patients’ lives is deemed to be minor whereas the increased knowledge of the health 
economic aspects of these diseases may serve as a knowledgebase for better and more cost-
effective use of healthcare resources in the future, which will benefit patients as well as 
society at large.   
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4 RESULTS 
4.1 COST-UTILITY ANALYSIS OF ANTI-TNF TREATMENT FOR RA (PAPER I & 
PAPER II) 
Register data from the SRQ was used to model the cost-effectiveness of anti-TNF use in 
Swedish clinical practice. Paper I only assessed infliximab as first-line treatment and paper II 
evaluated etanercept alone and all anti-TNFs combined (either as monotherapies or in 
combination with MTX), both as first and second-line biological treatment.   
In all, the results from these papers indicated that as the anti-TNFs have been used in Swedish 
clinical practice, it has been used in a cost-effective manner on a macro-level for first-line 
treatment. The base case scenario produced ICERs of €22 – 54,000, dependent on sub-
population analysed for the combination regimens (i.e. combination of anti-TNF and MTX). 
The results further indicated a lower cost-effectiveness ratio for first-line biological 
treatments than second-line. For second-line biological treatment, the results were not as clear 
on macro level, rather cost-effective use of these therapies was primarily seen in those with 
high underlying disease progression. 
The results indicated that the rate of progression in the comparator arm was of greatest 
importance for the cost-effectiveness results. The rate of progression for the comparator was 
based on published literature as it was not available in the register. At the time of the two 
different papers, there was no consensus in literature regarding the actual rate of progression 
in absence of anti-TNF therapy, instead it ranged between 0.03 – 0.13 HAQ / year in different 
publications. At the time of publication of paper II, more studies had been published 
supporting a lower value than used in paper I (which was 0.065 HAQ/year). A threshold 
analysis was therefore performed as part of paper II, which indicated a cut off point for cost-
effectiveness at a rate of progression without treatment at 0.045 HAQ points/year (i.e. 
exceeding this would give a cost-effective result), illustrated in Figure 7. The results from 
these analyses indicated that it is more cost-effective to treat patients with higher rates of 
underlying disease progression.  
The results were also sensitive to age at initiation of anti-TNF therapy. This is driven by the 
effect these therapies have on maintaining work ability, decreasing the indirect costs 
associated with RA. As patients above 65 are assumed not to work, this benefit is not 




Figure 7. Cost per QALY gained at different progression rates of the comparator for the first (a) and the second (b) 
biological treatment received 
4.2 EVALUATION OF REGISTER- VS RCT-BASED COST-UTILITY ANALYSIS 
OF ANTI-TNF TREATMENT FOR RA (PAPER III) 
An early model based on phase III RCT data on infliximab concluded that it was a cost-
effective therapy for RA (93). The results from paper I indicated that infliximab had been 
used cost-effectively in Swedish clinical practice. In paper III, the precision of the predictive 
cost-effectiveness assessment based on a phase III trial was evaluated with the use of register 
data from the SRQ. This was performed on infliximab therapy, as data from both the phase 
III trial and the Stockholm part of the SRQ (STURE) were available.  
The results indicated that approximately half (48%) of the patients receiving infliximab 
therapy in clinical practice would have been eligible for inclusion in the pivotal phase III trial. 
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This population constituted the matched population from the registry. The other two cohorts 
were the registry cohort and the RCT cohort.  
The results for the three patient cohorts ranged from cost saving to €2,400/ QALY gained, 
and a range of €24,900 to €26,000 /QALY gained when the ATTRACT and STURE 
assumptions were used, respectively. Sensitivity analyses indicated that the inclusion of 
placebo effect had the largest effect on the results, increasing the cost per QALY gained to 
approximately €50,000 for all patient cohorts.  
The results further indicated that the treatment effect of infliximab measured in clinical trials 
and clinical practice resulted in comparable cost-effectiveness ratios, as calculated by using a 
modelling approach, whereas the assumptions made in relation to the effectiveness data and 
the chosen comparator had a large impact on the results. Within each set of assumptions, the 
different cohorts produced similar results also after probabilistic sensitivity analysis (see 
Figure 8).  
 
Figure 8. Results from probabilistic sensitivity analysis comparing three different cohorts and two sets of assumptions in 
relation to the effect data 
4.3 HOSPITAL COMPARISON OF STROKE CARE (PAPER IV) 
Paper IV estimated health outcomes and resource use one year after stroke, and presented a 
comparison of performance between hospitals and regions while accounting for differences in 
patient mix.  
The results indicated that the remaining effect one year post-stroke on different aspects of 
health outcomes was substantial; 26% of the patients had died, approximately 5% had a 
recurrent stroke and almost 40% of the survivors had remaining functional disability. Still, 
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75% of the surviving patients had rated their general health as good. The results further 
indicated substantial use of healthcare resources. The use of county council resources 
amounted to 22 inpatient bed days and 23 outpatient visits (speciality care and primary care 
combined) on average. Additionally, the use of municipal social services amounted to 151 
hours of home care service and 13% of the population living in special housing, on average 
one year post stroke. The variations between hospitals in these estimates were large. The 
confidence intervals of the crude rates on hospital level indicated that there were statistically 
significant differences between hospitals, and several hospitals had significantly lower or 
higher crude rates than the patient-level average of the whole study population. Variations 
were also identified between hospitals within the same region. 
The results indicated that there were significant differences in health outcomes between 
hospitals also after adjusting for patient mix (Figure 9). Six hospitals performed better in 
terms of health outcomes (marked with light green) and six hospitals performed worse 
(marked with light red) compared to the other hospitals, with statistically significant deviation 
on several indicators for health outcomes.  
Regarding resource use, there were also significant differences in the adjusted comparison 
between hospitals (Figure 10). The range of inpatient stay spanned from –8 days to +16 days 
compared to the mean, and the corresponding differences for outpatient visits spanned from   
-7 visits to +7 visits for speciality care and -10 to +21 visits for primary care. There were also 
substantial deviations for municipality care.  
Most hospitals showed a pattern with higher levels of resources of one kind (e.g. inpatient 
care) and lower levels of another (e.g. outpatient care or special housing). However, five 
hospitals had lower levels of resources use (marked with light green) and five hospitals had 
the opposite results; higher levels of resource use compared to the other hospitals (marked 
with light red). Within regions, trends could be identified with regards to the division of 
outpatient visits between specialist and primary care; e.g. lower number of primary care visits 
whilst higher levels of specialist care as in RS, and the opposite relationship as in VGR. 
Differences in health outcomes and resource use between hospitals for patients with stroke 
were substantial and not entirely explained by differences in patient mix. No conclusions can 
be drawn as to which resource type provided the best health outcomes, and no clear 
relationship between resources and health outcomes was detected. However, a few hospitals 
had both worse health outcomes and more resources, implying a less cost-effective healthcare 
delivery or value of care. 
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Figure 9. Adjusted deviation in health outcomes one year post-stroke. Patients with a stroke in 2010. Colour markers indicate better (green) or worse (red) health outcomes if having significant deviations in 
only one direction for at least three indicators of outcome. Exception was made to “full-time work ability”, as this variable concerned a sub-population and the data used were based on sick leave, which is 
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Figure 10. Adjusted deviation in resource use one year post-stroke. Patients with a stroke in 2010. Colour markers indicate higher (red) or lower (green) level of resources, highlighted in cases where there 
was a significant deviation of “inpatient care” and “move into special housing” in only one direction. Limitation to these two variables was done in accordance with findings in paper V which demonstrated 
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4.4 COST OF STROKE BY FUNCTIONAL DISABILITY (PAPER V) 
Paper V estimated the total costs of stroke, stratified by functional disability and stroke type 
up to two years post-stroke. 
The total per-patient cost during first year for all patients was approximately 
470,000 SEK/€50,000 and 370,000 SEK/€39,000 for patients with ICH and IS respectively. 
The corresponding costs for the second year were 420,000 SEK/€45,000 and 350,000 SEK 
/€37,000. Indirect costs constituted 12-20% of the total costs dependent on years passed after 
stroke and stroke type. 
The results indicated a relationship between level of functional disability and cost during both 
the first and the second year following the stroke (Figure 11). During the first year, costs 
increased with each level of functional disability, and patients with ICH were associated with 
higher total average costs for any level of functional disability (apart from dead) compared to 
patients with IS. These cost differences were primarily driven by the differences in use of 
inpatient care and special housing. The total average cost ranged from 200,000 SEK/€21,000 
to 1,100,000 SEK/€120,000 for the first year following a stroke, for the different patient sub-
groups. mRS 5 was associated with an almost four-fold increase in costs compared to      
mRS 0-2 for patients irrespective of stroke type.  
The results further indicated that there were remaining costs for stroke patients in the second 
year after stroke, especially for patients with continuous functional disability (mRS 4 and 
mRS 5). ICH was still associated with higher costs for most groups as well as in total, 
although with a smaller difference to IS than for the first-year costs. The cost increase of 
mRS 4 or 5 compared to mRS 0-2 in the second year was approximately eight-fold. For the 
second year after stroke, the costs of municipality resources were the main drivers of total 
costs. 
Stratified analyses by age indicated that for any given age category, there was an increase in 
total costs for each level of functional disability during the first and second year, although 
being in the worst state of functional disability (mRS 5) was associated with slightly lower 
costs than mRS 4 during second year for older age groups (see Figure 12 for IS patients as 
example). Further, the youngest age group was associated with the highest cost, irrespective 
of level of functional disability during the initial year. This was primarily driven by higher 





Figure 11. First (a) and second (b) year cost by functioning ability and stroke type, per patient 
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Figure 12. Total cost (SEK) by functional disability and age during first (a) and second (b) year post ischemic stroke
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5 DISCUSSION 
5.1 STUDY FINDINGS 
The findings of the papers in this thesis have provided valuable insights into the health 
economics of RA and stroke and the use of quality register data in such assessments. 
The results from papers I and II indicated an overall cost-effective use in clinical practice of 
anti-TNF therapy for RA as first-line therapy on macro level in Sweden, compared to a 
scenario of no biological treatment. The results were, however, sensitive to the underlying 
disease progression in the absence of biological treatment. Almost all therapies investigated 
have provided good societal value for the money (in Sweden) at a progression of 0.045 HAQ 
points per year for the comparator. Hence, the underlying disease progression of each 
individual patient is of importance for cost-effective use of therapies. Data from the SRQ 
were used for effectiveness of anti-TNF treatment over HAQ and DAS28 categories, as well 
as discontinuation rates, providing valuable information on the use and effect of treatment in 
clinical practice.  
There are pros and cons with register data and RCT data, and views on which data source is 
more reliable and more appropriate in health economic analyses are not coherent. Paper III 
demonstrated that the effectiveness data from two different types of sources give comparable 
incremental cost-effectiveness estimates when the same comparator was used and the same 
assumptions were applied to the data and model. This was demonstrated with the example of 
infliximab treatment for RA. Although only half of the patients receiving infliximab therapy 
in clinical practice were found eligible for inclusion in the phase III clinical trial, this did not 
translate into any major difference in cost-effectiveness results. Early economic evaluations 
based on RCT data are valuable but caution needs to be taken to the comparator used and 
assumptions made if the results are to be used as predictions for cost-effectiveness of a new 
therapy in clinical practice and used for policy decisions. In addition to the data used from 
SRQ in papers I and II, SRQ data provided valuable information on patient characteristics, 
enabling matching of the patients to RCT inclusion criteria.  
Paper IV demonstrated that the impact of stroke on health outcomes and resource use was 
substantial, and that differences in these stroke-related indicators between hospitals were not 
entirely explained by differences in patient mix, indicating geographical inequalities in 
Swedish stroke care. Healthcare organization of regions and other structural features, could 
potentially explain parts of the differences identified. No clear relationship between resources 
and outcomes were detected in this paper, indicating that there is potential in ensuring more 
cost-effective use of current resources. As consequences of stroke are life-long for many 
patients, (although only estimated for the first year in this study), the total effect for the 
patients and society at large is likely to be even larger than demonstrated in this study. The 
results further highlighted the importance of including a wide range of both health outcomes 
and resources in studies of stroke, as this is a necessity if conclusions are to be drawn on the 
total effects of stroke. Data from Riksstroke on health outcomes and patient characteristics 
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(important for case-mix adjustment) were used for this paper, including PROMs that has been 
collected by Riksstroke. 
The costs following a stroke were extensive during the first year and beyond, as indicated by 
paper V. The results of this paper indicated increasing costs with worse functional disability, 
and higher costs for patients with ICH compared to IS during the first year after stroke. 
Further, the results indicated higher costs for lower age groups, driven by indirect costs and 
more inpatient care than for older patients. The results also demonstrated the importance of 
having a scope beyond the healthcare budgets when assessing the costs of stroke, specifically 
highlighted by the more long-term costs of municipality financed care identified in the 
results. Riksstroke provided data on level of functional disability, enabling stratification of 
costs. 
The papers of this thesis have highlighted diverse possibilities of using quality register data in 
health economic analyses for diseases associated with a chronic condition. It has been shown 
that data from quality registers can provide valuable information when:  
• Assessing the real-life effectiveness of therapy, which through health economic 
modelling have given indication of its cost-effectiveness in clinical practice  
• Evaluating the predictive RCT assessment as well as the impact of different patient 
populations on the cost-effectiveness results 
• Assessing health outcomes and putting them in relation to resource use, as well as 
enabling comparison of hospital performance 
• Assessing resources and costs by level of functional disability  
5.2 CRITICAL EVALUATION OF STUDY METHODS  
All papers in this thesis were based on register data which is associated with both strengths 
and limitations. 
A major strength was that the registers used all have good coverage of the Swedish RA and 
stroke populations from the covered geographical regions of the papers, minimizing the risk 
of selection bias in the study populations. Still, as none of the studies had national coverage, 
caution should be applied to generalizing the results to other regions in Sweden or to other 
countries. The registration of a patient into a quality register is not automatically performed 
from the medical record, instead it requires manual registration of specific variables after 
diagnosis. This procedure ensures that only patients with confirmed correct diagnoses are 
registered in the quality registers whereas there is an over registration of diagnoses with RA 
or stroke in the patient administration systems. The study populations were based primarily 
on the data from the quality registers, ensuring only patients with confirmed diagnoses were 
included in the assessments of this thesis.  
In papers IV and V, several registers were linked to each other by using the Swedish personal 
identification number, allowing for a more holistic approach to the health economic analyses 
in these papers. This bottom-up approach of using register data allows for large datasets to be 
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included in the analysis which strengthens the statistical stability of the results, is less costly 
and more time-efficient than performing a primary data collection from the patients. The size 
of the study populations were also large enough to perform sub-group analyses and stratifying 
the patient population for the different analyses. However, not all resources could be assessed 
using this methodological approach, for example information on informal care, pre-hospital 
care, municipality-financed home healthcare (performed by medical staff) or detailed 
information on rehabilitation received were not available in the registers and hence not 
assessed.  
Register based studies are also associated with common limitations that need to be considered 
when interpreting the results, such as incorrect registrations, missing data or incomplete data. 
When performing data management on the datasets, corrections were made to incorrect data 
to minimize the impact of this limitation. This was however only done in cases where there 
was a logical maximum or minimum value (e.g. maximum value of 365 inpatient days during 
one year). No other adjustments, like for example imputation of missing data, were 
performed. Missing data may have an impact on the results if the patient population with 
missing data differ from those with complete data. In cases where the coverage of a variable 
was too low, the variable was instead omitted from the statistical analyses in order not to lose 
these patients in the statistical models. In paper IV, for example, data on stroke severity by 
National Institutes of Health Stroke Scale (NIHSS) was omitted for this reason.  
Additionally, the quality of registrations for healthcare contacts in PAS (e.g. primary care 
diagnoses) differed between hospitals and regions, introducing a systematic error when 
assessing differences between hospitals and regions as in paper IV. To minimize the impact 
of this, the total number of resources utilized were studied in both paper IV and V (not only 
stroke-related). The greater part of the healthcare resource use was nevertheless found to be 
stroke-related in a sensitivity analysis in one of the regions with a high frequency of reporting 
of diagnosis codes. This sensitivity analysis indicated that applying a definition of ICD-10 
codes directly related to stroke (acute or sequelae codes) would underestimate the resource 
use, as many healthcare contacts had codes likely related to consequences of stroke (e.g. eye 
exams and speech difficulties) but without a complementing stroke-specific code. Another 
option would have been to adjust for pre-stroke resource levels when assessing resources 
post-stroke, in which case the patients would act as their own controls. This approach 
requires defining a time frame prior to stroke assessed as baseline and a strategy on how to 
handle patients who die, as these patients may incur less resources after a stroke than prior to 
the stroke. A sensitivity analysis performed for paper V also indicated that resource use 
increased the months just prior to the stroke, which may actually be related to the upcoming 
stroke event. An additional option would have been to compare the resources to a matched 
control group from the general public. However, such data was not available within the scope 
of the larger Sveus-program that this study was a part of. In paper IV, the case-mix adjusted 
comparison of resources between hospitals were adjusted for pre-stroke inpatient bed days as 
a proxy for comorbidities and how resource demanding the patient population was prior to 
the stroke. In paper V on the other hand, resource use was stratified based on functional 
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disability (by applying an approximation of mRS), enabling the use of mRS 0-2 (good 
functional ability) as reference population in assessing increasing costs with worse functional 
disability post stroke. Still, it should be noted that although the transformation to mRS from 
variables in Riksstroke is validated (94), it does not provide a distinction between mRS 0, 1 
and 2 as in the original mRS instrument. The results based on functional disability in this 
study may nevertheless provide deeper insights and input when assessing healthcare 
interventions post stroke (in e.g. health economic modelling). However, for assessments of 
preventive interventions a comparison needs to be made to the pre-stroke resources and costs.  
Health outcomes were retrieved from several sources and consist of a mixture of hard 
endpoints and patient-reported outcome measures, the latter dependent on participation of 
patients and their ability to answer the questions. For some stroke patients, these questions 
were completed by their next of kin, possibly rendering other results than if the patient would 
have answered the questions themselves. These patients were most likely severely impaired 
after stroke, which may give rise to systematic errors. It is however unlikely that such errors 
differ between hospitals or regions, and impact on the conclusions in paper IV are expected to 
be minor.  
In all comparative studies or economic evaluations, it is important to ensure that the 
comparisons made are based on equivalent patient populations to be able to draw any 
conclusions from the analyses. In papers I-III a comparator arm of no biological treatment 
was included in the economic evaluations of anti-TNF treatment, to enable comparative 
analyses. However, when using register data for assessing the cost-effectiveness of 
interventions, there is a challenge in choosing a comparator population for the analysis. The 
comparative scenario needs to be conducted for the same population as the evaluated 
treatment alternative, ensuring that only the effect of the treatment is evaluated and that no 
differences in patient populations are incorporated in the analysis. The patients in the 
comparator arm needs to be matched to the ones receiving therapy. However, as a therapy is 
introduced to the market and becomes the new standard, the patients who receive the therapy 
will not be similar to those not receiving it, because of contraindications or other reasons. 
Hence, a matched comparator group is simply not available in the register. Alternatively, 
historical data could have been used (before introduction of the new therapy) for comparison. 
However, this may not be entirely representable as other advances in healthcare over time 
may also influence health outcomes or resource use (e.g. better diagnostics, other treatments, 
routines for visits etc.), therefore altering the results. For the economic evaluations in papers 
I-III, historical data from the register was not available and hence not a possibility for these 
assessments. Instead, progression for the comparator arm was based on published literature, 
choosing estimates based on populations as close as possible to the indication of anti-TNF 
therapy (i.e. failed two conventional DMARDs). In paper III, a matched cohort was identified 
from the register dataset to assess one patient population in real life that was similar to the 
population included in the RCT.  
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Another alternative to using a comparator of no biological treatment would have been to 
compare the anti-TNFs to each other in papers I and II. Such an analysis would have to 
account for differences in the patient populations due to patient/physician preferences for the 
therapy/mode of administration (and also potentially the clinical budget impact), which may 
impact the choice of therapy. Additionally, the different therapies became available at 
different points in time which may affect behaviour (e.g. possibility to switch to other 
therapies, increased experience with therapies) and patient mix (more severe cases for the 
biological DMARDs first introduced to the market). However, TLV has concluded that there 
is no significant difference in effectiveness and adverse events profile of these therapies and 
any comparison between the different anti-TNFs comes down to cost-minimization in the 
absence of a head-to-head trial (www.tlv.se).  
In papers IV and V, there was no evaluation of one intervention compared to another. Still, 
comparability between different populations were necessary to account for in a proper way. 
In paper IV, comparability between hospitals was ensured by adjusting the results for 
differences in patient mix. However, not all aspects of the patients’ conditions could be 
controlled for because of lack of data, for example time to hospital (important for acute 
treatment of stroke) which was simply not available. Additionally, stroke severity data 
(NIHSS) is collected within Riksstroke and has been shown to be important for predictions of 
outcome (99), but NIHSS had too low coverage for the study population in paper IV to be 
included as a case-mix variable. Level of consciousness, which has been shown to be a strong 
predictor for outcome and also a good approximation of the full NIHSS in predictions (100), 
was however included whereby this limitation should have minor impact on the overall 
conclusions. In paper V, sensitivity analyses were performed by stratifying the estimated 
costs by age as well, to assess the impact of another potentially strong determinant of costs.   
5.3 POLICY IMPLICATIONS 
Health economic analyses are used to aid decision making in healthcare to ensure efficient 
use of healthcare resources. This is accomplished at several different levels, from 
understanding burden of a disease and where gains can be attained, to a specific assessment 
of a therapy and whether it should be paid for within the general reimbursement system/ 
covered in health plans or not. In Sweden, economic evaluations have been used to a large 
extent in decision making about healthcare policies and in treatment decisions (101). 
This thesis has shown that quality register data can be used in a wide range of health 
economic analyses, providing increased knowledge about the health economic consequences 
of diseases and therapies. In combination with other data sources, this is an important base for 
making informed policy decisions and to understand also on hospital level where cost-
effective improvements of healthcare delivery may be attained.  
In economic evaluations of therapies at market introduction, the use of RCT data may 
provide a good prediction of real life cost-effectiveness on which reimbursement decisions 
are made. In an RCT based analysis, the comparator is often placebo which is not a real 
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treatment alternative in clinical practice. One may argue that this is not a relevant comparator 
for a decision on resource allocation as the results indicate whether resources should be spent 
on the therapy or placebo (which is not offered in clinical practice). On the other hand, it may 
be argued that the effect society should pay for is the placebo-controlled effect and therefore 
is the relevant comparison for basis of the decision of resource allocation. In any case, 
caution needs to be taken of the assumptions made in relation to the data and sensitivity 
analyses should be performed to better mirror the projected use in clinical practice in addition 
to the RCT-based analyses, to give a range of the results as a basis for the decision on 
resource allocation. As the therapies evaluated become standard therapies, as experiences 
from them changes the use or as new therapies enter the market, it is of importance to 
perform follow-up health economic evaluations to ensure a continuous cost-effective use in 
clinical practice.  
The introduction of biological DMARDs have revolutionized RA-care by offering effective 
treatment and prolonging time to progression for the patients (14). These treatments have 
been recommended as treatment for RA in Sweden (11), which comes with an additional 
cost. The results from papers I and II indicated that whether or not these therapies are used in 
a cost-effective manner will be determined by the patient’s age at treatment initiation and the 
rate of progression for the patient in the absence of biological treatment. Patient selection 
based on age may not be warranted as it would impose inequalities and discrimination in 
healthcare, which is not desirable. However, the patient’s disease projections without 
biological treatment should be taken into consideration if healthcare spending are to be used 
cost-effectively. Policies and recommendations on cost-effective use of these treatments 
could be further refined for specific sub-groups of the patient population as more sub-groups 
analyses of cost-effectiveness are presented. Still, other important principals for decisions on 
resource allocation should also be considered, such as equality, severity of disease, patient 
need and other ethical aspects. 
To improve health equity and increase value of healthcare, it is important to first identify 
possible inequalities in healthcare that considers both health outcomes and resources. Sweden 
has favourable conditions for such an analysis due to the quality and availability of national 
registers, both quality registers and other national registers. Based on such data, the results of 
paper IV has demonstrated statistically significant variations in health outcomes, not 
explained by the detected differences in patient mix. Thus, this indicated inequalities on 
hospital level in Swedish stroke care delivery, during both the acute phase and beyond. These 
results could help foster the sharing of best practices between hospitals and between regions, 
changing health policy and healthcare delivery at hospitals and within regions. This effect can 
be further enhanced when comparisons are performed and transparently communicated on a 
continuous basis. Healthcare organization of regions and other structural features, could 
potentially explain parts of the differences identified in paper IV. These factors are possible 
to control on hospital or regional level, whereby improvements are possible which would 
most likely be cost-effective. Potentially both an increase in health outcomes for patients with 
stroke in Sweden and more efficient use of resources could be achieved. Additionally, there is 
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most likely a possibility to decrease inequalities between patients treated at different hospitals 
and in different regions. 
The results from paper V emphasize the importance of fast and efficient management of 
stroke patients to decrease the likelihood of permanent functional disability and the cost-
consequences associated with this attained disability. Also, interventions such as reperfusion 
therapy (thrombolysis and thrombectomy) that can dramatically improve outcome for IS can 
be cost-effective even if the initial cost may be high, due to the long-term costs associated 
with worse functional disability. The results of this paper also highlighted the importance of 
including all costs irrespective of who incurs them in such analyses, and not only assess the 
impact on separate budgets (e.g. clinical budget at a hospital) as this may lead to sub-optimal 
policy decisions for society at large. The need of continuous rehabilitation to maintain 
functional ability is also of importance, not only for the individual patient by reaching better 
health outcomes, but also for society at large, in decreasing the societal burden of stroke by 
keeping patients in better health states associated with lower costs. Due to the chronic nature 
of these disabilities, the long-term cost consequences are likely to be substantial. These 
results may hence be used as basis for policy decisions of management of stroke patients, by 
providing information on the cost-offset of keeping patients in levels of better functional 
ability. This may be useful both with regards to acute therapy and rehabilitation efforts. The 
results may further be used as input data in economic evaluations of interventions in stroke 
care.  
5.4 SUGGESTIONS FOR FUTURE RESEARCH 
Although quality registers are not designed for health economic purposes, they provide a 
unique opportunity to assess different diseases from a health economic point of view to help 
make efficient use of healthcare resources. This opportunity should be further explored in 
future research and more assessments should take advantage of linking data to other registers 
for holistic approaches in health economic analyses of diseases.  
The market entry of anti-TNFs provided an important treatment alternative and a potential for 
health improvement for patients with RA, halting disease progression and prolonging the 
time to functional disability. However, these therapies have been costly and have put a 
constraint on healthcare budgets whereby the health economic analyses of these therapies 
have been important to ensure cost-effective use. Future research should continue to assess 
different sub-populations, new treatment regimens or dosing schemes (for example with 
treatment holidays) to ensure as cost-effective use as possible while maintaining the positive 
health effects of these therapies. To date, there is scarce evidence of difference in effects 
between different biological DMARDS (102) and head-to-head trials are needed to assess 
this. When such data becomes available, it is important to perform follow-up cost-
effectiveness assessments as basis for policy decisions of the comparative cost-effectiveness 
of different options of biological DMARDs. 
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In stroke, thrombolysis and thrombectomies have had a similar effect on patient outcomes for 
stroke patients as biological DMARDs have had for RA, as they have been shown to decrease 
the risk of long-term functional disability of stroke. These therapies are associated with an 
increased cost, but recent publications based on clinical trial data suggest that their use are 
cost-effective (78, 103-106). Quality registers for stroke should be used to continuously 
monitor the effectiveness of these new acute therapies and to provide data for cost-
effectiveness assessments of these therapies in clinical practice. This is important to ensure 
that the treatments are used in a cost-effective manner in clinical practice. As thrombectomy 
is not available yet at all hospitals in Sweden it should be possible to match patients for an 
economic evaluation of its use in clinical practice, as a complement to evaluations performed 
based on RCT data (106). In such assessments, it is of importance to model the long-term 
effect of this chronic condition and not only for the year the patients are monitored within the 
quality register. The results in paper V can be used for populating the model with costs based 
on functional disability and stroke type during the first and second year, thereafter 
assumptions need to be made to the long-term effects. As stroke is not a progressive disease, 
rather the condition reached after one year is expected to be relatively static in absence of 
new events, the costs of the second year related to the stroke could be assumed to prevail 
during following years as well. The vast experience of evaluating treatments for RA to model 
life-time consequences, such as choice of comparator and sensitivity analyses related to this, 
as well as necessary assumptions of long-term effectiveness, should be applied in any model 
for an evaluation of stroke therapy. 
Additionally, updated costs and utility assessments of RA related to health outcomes are 
warranted as these may have changed over time in a Swedish setting. In stroke, utility 
assessments and its relation to functional disability and resource use/costs would also be of 
great interest. Such studies would provide deeper insights into the health economic 
consequences of stroke and RA to date, and also provide updated data for use in economic 
evaluations, increasing the validity and predictability of such analyses.  
5.5 LEARNINGS AND CONCLUSIONS 
This thesis has demonstrated the strengths and limitations of using data from quality registers 
for health economic analyses in patients with chronic conditions. This thesis has used the data 
for several purposes, building on the learnings from each paper included in this thesis: 
• Paper I included one quality register data source, complemented with published data. 
An assessment was made on one therapy in a health economic model, modelling 
long-term effects in a chronic disease. Challenges in using register data for real life 
cost-effectiveness assessments were addressed. 
• Paper II included three similar quality register sources, including several treatment 
options and lines of biological therapy. To enable this analyses, modifications to the 
health economic model was necessary and more extensive sensitivity analyses were 
performed, increasing the understanding of drivers of the results. 
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• Paper III included two different data sources (quality register and RCT) and thereby 
two different patient populations, in order to assess the impact of different sources 
and their characteristics as well as the impact of assumptions made in the model on 
the results. For this paper, a matched cohort from the register was elicited to enable 
comparison to the RCT cohort to ensure that similar populations were used in the 
evaluation.  
• Paper IV expanded the number of data sources, enabling a larger number of variables 
to be included, which required work with data linkage as well as assessing differences 
in data quality and registration between the PAS of different regions. Identification 
and estimation of both health outcomes and resource use from the compiled register 
dataset was practiced. Instead of comparing outcomes between two treatment 
alternatives, this paper compared outcomes and resources between different hospitals 
and regions. Rather than matching populations for the different hospitals, the analyses 
were adjusted for differences in patient mix by the use of statistical analysis. 
• Paper V transformed the resources into costs, using the costing aspect of health 
economics. This was done by functional disability and stroke type, enabling the use of 
these results in future health economic evaluations of therapies in stroke care. 
Stratified analysis was also performed by age. 
The quality registers are not designed for health economic purposes, but this thesis has 
demonstrated their valuable contribution in health economics by providing a valid base of 
data and opportunities to: 
• Assess real life effectiveness of treatments in economic evaluations 
• Retrieve data on health outcomes and patient characteristics, which are essential in:  
o Measuring health outcomes and relating them to levels of resource use 
o Enabling hospital comparisons of performance and performing case-mix 
adjustment of results 
o Enabling stratification of cost estimates by level of health outcome 
o Provide input parameters for future economic evaluations 
In order to assess the full health economic aspects of chronic conditions, quality registers play 
an important role, but there is a necessity to combine the quality register data with other 
registers or other data sources, published literature and potentially also conduct modelling to 
account for the long-term effects. Nevertheless, any quality register that wants to ensure that 
the data can be used for health economic analyses and provide valid data for such analyses, 
should consider to: 
• Ensure long-term follow-up of the patients (espcecially in chronic conditions) 
• Collect data on: 
o Patient characteristics, including the clinical markers important for the 
patient’s prognosis 
o Treatments received  
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o Health outcomes that are common as measurements of treatment outcome (e.g 
in RCTs), as well as estimation of quality of life or utilities 
o Resource use (quantifyable) outside the healthcare sector, e.g. informal care 
The quality registers and other register data sources can be utilized to a greater extent in 
different assessments which share the aim of improving healthcare delivery and increasing its 
value – either by assessing level of health outcomes, processes and resources used; enabling 
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